Can-Fite BioPharma (NYSE:CANF) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report issued on Monday. The firm set a “hold” rating on the stock.

Can-Fite BioPharma Trading Up 0.5 %

CANF stock opened at $1.98 on Monday. The firm’s 50-day moving average is $2.16 and its two-hundred day moving average is $2.12. The company has a market capitalization of $7.01 million, a price-to-earnings ratio of -1.11 and a beta of 1.53. Can-Fite BioPharma has a 52 week low of $1.66 and a 52 week high of $3.33.

Can-Fite BioPharma (NYSE:CANF) last released its earnings results on Thursday, March 28th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). Can-Fite BioPharma had a negative return on equity of 113.75% and a negative net margin of 1,027.46%. The firm had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.20 million. On average, equities research analysts predict that Can-Fite BioPharma will post -0.03 earnings per share for the current year.

Institutional Trading of Can-Fite BioPharma

A number of hedge funds and other institutional investors have recently made changes to their positions in CANF. Schechter Investment Advisors LLC purchased a new stake in shares of Can-Fite BioPharma during the fourth quarter valued at $44,000. Armistice Capital LLC purchased a new position in Can-Fite BioPharma in the 1st quarter worth about $756,000. Finally, Virtu Financial LLC acquired a new stake in Can-Fite BioPharma during the 2nd quarter worth about $52,000. 21.00% of the stock is currently owned by institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.